Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer
Launched by CHINESE UNIVERSITY OF HONG KONG · Feb 22, 2023
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a Chinese medicine called Yunzhi Essence, which is made from a mushroom known as Coriolus Versicolor. The goal is to see if this treatment can help improve the quality of life for patients who have advanced-stage cancer, meaning their cancer is serious and may not be curable. Participants will be randomly placed into two groups: one will receive the Yunzhi Essence, while the other will receive a placebo, which looks like the real treatment but contains no active ingredients. The study will last for six months, and researchers will monitor how each group feels throughout the trial.
To be eligible for this trial, participants must have a diagnosis of advanced cancer and be expected to live for at least six months to two years based on their doctor's assessment. They should also be able to understand and participate in the study, which means having a certain level of mental clarity. However, people who have allergies to Chinese medicine, cannot swallow, or are severely ill may not qualify. This trial is not yet open for recruitment, but it aims to help individuals with advanced cancer find better ways to manage their symptoms and improve their overall well-being.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with advanced cancer according to the definition from American Cancer Society;
- • According to the experience of the doctor, by using Palliative Prognostic Index (score\>4), integrated with past cases and professional knowledge judged to have life expectancy not less than six months to two years;
- • Abbreviated mental test (AMT) score of 6 or above;
- • Voluntarily participate in this clinical trial and sign the informed consent form (acceptance of close relatives signed informed consent on behalf of the patient);
- • Refer to the national standard for Clinic terminology of traditional Chinese medical diagnosis and treatment-Part 2:Syndromes/patterns, syndrome of "damp heat spleen" and "spleen deficiency with water stop" (Fulfill 2 of the main symptoms and 2 of the secondary symptoms).
- Exclusion Criteria:
- • Patients with a history of allergy to traditional Chinese medicine or Yunzhi;
- • Patients who required nasal feeding or difficulty swallowing;
- • Patients with comatose/semi-conscious, cognitively impaired with dementia/confusion, physically too ill with extremely poor general condition, or there was a language barrier.
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Zhixiu Lin
Principal Investigator
Hong Kong Institute of Integrative Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials